

Su (2012): Ex. 2045

Pharmacokinetics of Saxagliptin

Supplemental material to this article can be found at: <http://dx.doi.org/10.1002/jcsm.1112>

1332-0003/2012/1341-1342/09
Drug Metabolism and Disposition
Copyright © 2012 by The American Society for Pharmacology and Experimental Therapeutics
DOI: 10.1002/jcsm.1112

Characterization of the In Vitro and In Vivo Disposition and Cytochrome P450 Inhibition/Induction of Saxagliptin in Human

Hong Su, David W. Boulton, Anthony Barros Jr., Lifen Wang, K. Ramaswamy A. Iyer, W. Griffith Humphreys, and ...

Departments of Pharmaceutical Candidate Optimization P.S., A.B., L.W., R.A.I., Clinical Pharmacology (D.W.B.), and Radiochemistry R.C., S.J.B.), Bristol-Myers Squibb, Princeton, NJ

Received March 2, 2012; accepted April 11, 2012


ABSTRACT:
Saxagliptin is a potent dipeptidyl peptidase-4 (DPP-4) inhibitor used for the treatment of type 2 diabetes and disposition of [¹⁴C]saxagliptin in male subjects after a single 50-mg dose was rapidly absorbed (T_{max}, 0.5 h) and eliminated with a half-life of 22 h. The mean pharmacokinetic parameters of saxagliptin in male subjects after a single 50-mg dose are summarized in Table 1. The mean plasma concentration of saxagliptin at 12 h was 22.1% of the administered dose, and 22.1% was excreted in the urine. The mean plasma concentration of saxagliptin at 12 h was 22.1% of the administered dose, and 22.1% was excreted in the urine and feces. The mean plasma concentration of saxagliptin at 12 h was 22.1% of the administered dose, and 22.1% was excreted in the urine and feces.

Introduction
The dipeptidyl peptidase-4 (DPP-4) inhibitors are a class of type 2 diabetes mellitus (Schiffman et al., 2007). Saxagliptin is a potent DPP-4 inhibitor used for the treatment of type 2 diabetes mellitus (Schiffman et al., 2007). Saxagliptin is a potent DPP-4 inhibitor used for the treatment of type 2 diabetes mellitus (Schiffman et al., 2007).

Parts of this work were previously published in: Su H, Wang L, Cao X, Boulton DW, Humphreys WG, Barros AJ, Iyer RA, et al. (2012) In vitro and in vivo characterization of the disposition and cytochrome P450 inhibition/induction of saxagliptin in human. *Journal of Clinical Pharmacology* 52:1332-1342. doi:10.1002/jcsm.1112

ABBREVIATIONS: DPP-4, dipeptidyl peptidase-4; HPLC, high performance liquid chromatography; HPLC-MS/MS, high performance liquid chromatography-mass spectrometry; MRM, multiple reaction monitoring; DMSO, dimethyl sulfoxide.

JTX-130 Page 6 of 12



Ex. 2045 at 6